Skip to main content
. 2013 Mar 15;187(6):648–657. doi: 10.1164/rccm.201205-0880OC

Figure 1.

Figure 1.

Diminazene aceturate (DIZE) treatment prevents pulmonary hypertension (PH) and associated cardiac hypertrophy. (A) Coincubation with DIZE (100 μM) increases the enzymatic activity of recombinant human angiotensin-converting enzyme 2 (ACE2) in vitro. (B) Measurement of right ventricular systolic pressure (RVSP) in monocrotaline (MCT)-challenged rats. (C) Right ventricle (RV) hypertrophy reflected by the ratio of RV to left ventricle (LV) plus interventricular septum (S) weight ratio [RV/(LV + S)] in the MCT-induced PH study. (D) RVSP measurement in the hypoxia model of PH. (E) RV/(LV + S) values in hypoxia-exposed rats. (F) Measurement of RVSP in the model of PH secondary to bleomycin-induced lung fibrosis. (G) RV hypertrophy in the bleomycin study. (H) Effect of chronic DIZE treatment on lung ACE2 activity in the bleomycin model of lung injury. Data represent mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with control rats or rats treated with DIZE group. #P < 0.05 compared with MCT/hypoxia/bleomycin-challenged rats (n = 10 per group for MCT study; n = 6 per group for hypoxia experiments; n = 5 per group for bleomycin study). Bleo = bleomycin.